Full Breakdown
UK Pharmaceutical Sector Faces Investment Crisis
9/13/2025, 12:40:15 AM
Declining Investment in Pharmaceutical R&D
The UK pharmaceutical sector is experiencing a significant downturn in investment, according to a report released by the Association of the British Pharmaceutical Industry (ABPI) on September 10, 2023. The report highlights that investment in research and development (R&D) by pharmaceutical companies in the UK fell by nearly £100 million in 2023, marking a stark contrast to a global average growth rate of 6.6% per year. The UK’s growth rate has stagnated at just 1.9% annually since 2020, raising concerns about the country's competitiveness in the global pharmaceutical landscape.
The report also indicates a 58% decline in foreign direct investment (FDI) in UK life sciences since 2017, dropping from nearly £1.9 billion to £795 million. This decline has resulted in the UK falling from second to seventh place in global rankings for pharmaceutical investment. The ABPI has urged the government to address these issues by fostering a more competitive environment for investment, particularly in areas such as health data, artificial intelligence, and advanced therapy research.
Major Companies Reassess UK Operations
The recent decision by Merck, known as MSD in Europe, to abandon its £1 billion research center in London has intensified concerns about the UK’s pharmaceutical environment. This decision, which will result in 125 job losses, was attributed to the UK’s declining attractiveness for investment. Merck stated that the UK is "not internationally competitive," reflecting broader industry sentiments about the challenging business climate.
Similarly, AstraZeneca announced a pause on its planned £200 million expansion of its Cambridge research facility, citing ongoing disputes with the government over NHS drug pricing. This follows AstraZeneca's earlier decision to scrap a £450 million vaccine plant in Liverpool, both of which were initially seen as endorsements of the UK’s life sciences sector.
Industry Criticism and Government Response
Industry executives, including Paul Naish from Sanofi, have criticized the UK government for failing to create a viable roadmap for pharmaceutical investment. Naish emphasized that while the UK has world-class universities and scientists, the operational costs and regulatory environment are discouraging for drug development. The NHS's expenditure on medicines has also decreased to 9% of total healthcare spending, significantly lower than in countries like Germany and the US.
In response, a spokesperson from the Department for Science, Innovation and Technology (DSIT) defended the UK’s investment record, asserting that the country remains an attractive place for investment. The government has committed to investing £600 million in health data research and £520 million in the Life Sciences Innovative Manufacturing Fund, aiming to stimulate further private investment.
Conflicting Reports and Future Outlook
Despite government assurances, the pharmaceutical industry remains skeptical. The ABPI has warned that the current environment is leading to fewer medicines being available in the UK, as companies face rising clawback taxes and stringent pricing regulations. The ongoing negotiations between the government and pharmaceutical companies over drug pricing have yet to yield a resolution, further complicating the investment landscape.
As the UK grapples with these challenges, the future of its pharmaceutical sector remains uncertain, with industry leaders calling for urgent reforms to restore the country’s status as a competitive hub for pharmaceutical investment.
